Loading clinical trials...
Loading clinical trials...
BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study
Conditions
Interventions
BAX 326 (Recombinant factor IX)
Locations
42
Argentina
Instituto de Hematología y Medicina Clíncia Rubén Dávoli
Rosario, Argentina
UNIFESP - Universidade Estadual de Sao Paulo
São Paulo, Brazil
Specialized Haematological Hospital "Joan Pavel"
Sofia, Bulgaria
Hospital Dr. Sotero del Rio
Santiago, Chile
Hospital de San Jose
Bogotá, Colombia
Centro Medico Imbanaco
Cali, Colombia
Start Date
April 12, 2011
Primary Completion Date
June 29, 2017
Completion Date
June 29, 2017
Last Updated
May 20, 2021
NCT06379789
NCT06008938
NCT04645199
NCT07080905
NCT06700096
NCT06312475
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions